
Novel TK1 Inhibitor Demonstrates Rapid, Dose-Dependent Efficacy in Atopic Dermatitis in Ph 1 Trial
Corvus Pharmaceuticals' oral IL-2-inducible T cell kinase (ITK) inhibitor soquelitinib demonstrated significant efficacy over placebo in treating adults with moderate to severe atopic dermatitis, according to interim data from a phase 1 randomized …